Chronic stress and insulin resistance-related indices of cardiovascular disease risk, part I: Neurophysiological responses and pathological sequelae

Alternative Therapies in Health and Medicine

Volumn 13, Issue 4, 2007, Pages 46-52

  Innes, Kim E ^a   Vincent, Heather K ^b   Taylor, Ann Gill ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; SOMATOMEDIN C;

ADRENERGIC SYSTEM; AMYGDALOID NUCLEUS; AROUSAL; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC STRESS; DISEASE MODEL; DYSLIPIDEMIA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LIMBIC SYSTEM; LIPID BLOOD LEVEL; MENTAL STRESS; NEUROPHYSIOLOGY; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; AUTONOMIC NERVOUS SYSTEM; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLIC SYNDROME X; STRESS;

AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; STRESS;

EID: 34548580464     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Tex: American Heart Association; 2005.
2. Bonow RO. Primary prevention of cardiovascular disease: a call to action. Circulation. 2002;106(25):3140-3141.
3. Lopez-Candales A. Cardiovascular diseases: a review of the Hispanic perspective. Awareness is the first step to action. J Med. 2002;33(1-4):227-245.
4. Watkins LO. Epidemiology and burden of cardiovascular disease. Clin Cardiol. 2004;27(6 Suppl 3):III2-III6.
5. Pramparo P. The epidemiology of hypertension in South America. J Hum Hypertens. 2002;16 Suppl 1:S3-6.
6. Posner B, Franz M, Quatromoni P. Nutrition and the global risk for chronic diseases: the INTERHEALTH Nutrition Initiative. Nutr Rev. 1994;52(6):210-207.
7. Popkin B. The nutrition transition in low-income countries. Nutr Rev. 1994;52(9):285-298.
8. Mackay J, Mensah G. The Atlas of Heart Disease and Stroke. Geneva: World Health Organization; 2004.
9. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med. 2003;163(3):333-339.
10. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med. 2002;21(2):213-237. Review.
11. Grundy S. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F-29F.
12. Ginsberg H. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453-458. Review.
13. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci. 2003;73(19):2395-2411.
14. Reilly M, Rader D. The metabolic syndrome: More than the sum of its parts? Circulation. 2003;108(13):1546-1551.
15. Reaven P. Metabolic syndrome. J Insur Med. 2004;36(2):132-142.
16. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb. 2002;32(5-6):269-273.
17. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7(5):325-331.
18. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am. 2004;33(2):417-429.
19. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003;20(4):255-268.
20. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med. 2004;117(2):109-117. Review.
21. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24(3):278-301. Review.
22. Byrne CD. Programming other hormones that affect insulin. Br Med Bull. 2001;60:153-171. Review.
23. Innes K, Wimsatt J. Pregnancy-induced hypertension and insulin resistance: Evidence for a connection. Acta Obstet Gynecol Scand. 1999;78(4):263-284.
24. Egan BM. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep. 2003;5(3):247-254.
25. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99(16):2192-2217.
26. Singh RB, Kartik C, Otsuka K, Pella D, Pella J. Brain-heart connection and the risk of heart attack. Biomed Pharmacother. 2002;56 Suppl 2;257s-265s.
27. Bunker SJ, Colquhoun DM, Esler MD, et al. "Stress" and coronary heart disease: psychosocial risk factors. Med J Aust. 2003;178(6):272-276.
28. Bjorntorp P, Holm G, Rosmond R, Folkow B. Hypertension and the metabolic syndrome: closely related central origin? Blood Press. 2000;9(2-3):71-82. Review.
29. Hjemdahl P. Stress and the metabolic syndrome: an interesting but enigmatic association. Circulation. 2002;106(21):2634-2636.
30. Brunner EJ, Hemingway H, Walker BR, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation. 2002;106(21):2659-2665.
31. Everson SA, Lynch JW, Chesney MA, et al. Interaction of workplace demands and cardiovascular reactivity in progression of carotid atherosclerosis: population based study. BMJ. 1997;314(7080):553-558.
32. Jennings JR, van der Molen MW, Somsen RJ, Graham R, Gianaros PJ. Vagal function in health and disease: studies in Pittsburgh. Physiol Behav. 2002;77(4-5):693-698. Review.
33. Bjorntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med. 1999;16(5):373-383.
34. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13(6 Pt 2):99S-105S.
35. Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep. 2001;3 Suppl 1:S3-S9.
36. Ceconi C, Curello S, Ferrari R. Catecholamines: the cardiovascular and neuroendocrine system. Eur Heart J. 1998;19(Suppl F):F2-F6.
37. Gadegbeku CA, Dhandayuthapani A, Sadler ZE, Egan BM. Raising lipids acutely reduces baroreflex sensitivity. Am J Hypertens. 2002;15(6):479-485.
38. Beske SD, Alvarez GE, Ballard TP, Davy KP. Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2002;282(2):H630-H635.
39. Curtis BM, O'Keefe JH, Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002;77(1):45-54.
40. Karason K, Molgaard H, Wikstrand J, Sjostrom L. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol. 1999;83(8):1242-1247.
41. Miller AW, Sims JJ, Canavan A, Hsu T, Ujhelyi MR. Impaired vagal reflex activity in insulin-resistant rats. J Cardiovasc Pharmacol. 1999;33(5):698-702.
42. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53(4):897-902. Review.
43. Buchman TG, Stein PK, Goldstein B. Heart rate variability in critical illness and critical care. Curr Opin Crit Care. 2002;8(4):311-315.
44. Pumprla J, Howorka K, Groves D, Chester M, Nolan J. Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol. 2002;84(1):1-14.
45. Bernardi L, Sleight P, Bandinelli G, et al. Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study. BMJ. 2001;323(7327):1446-1449.
46. Carney RM, Blumenthal JA, Catellier D, et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol. 2003;92(11):1277-1281.
47. Everson SA, Kaplan GA, Goldberg DE, Salonen R, Salonen JT. Hopelessness and 4-year progression of carotid atherosclerosis. The Kuopio Ischemic Heart Disease Risk Factor Study. Arterioscler Thromb Vasc Biol. 1997;17(8):1490-1495.
48. Greenwood DC, Muir KR, Packham CJ, Madeley RJ. Coronary heart disease: a review of the role of psychosocial stress and social support. J Public Health Med. 1996;18(2):221-231.
49. Levenstein S, Smith MW, Kaplan GA. Psychosocial predictors of hypertension in men and women. Arch Intern Med. 2001;161(10):1341-1346.
50. Bjorntorp P. Endocrine abnormalities of obesity. Metabolism. 1995;44(9 Suppl 3):21-23. Review.
51. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition. 1997;13(9):795-803. Review.
52. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2(2):73-86.
53. Pike JL, Smith TL, Hauger RL, et al. Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an acute psychological stressor in humans. Psychosom Med. 1997;59(4):447-457.
54. Lucini D, Norbiato G, Clerici M, Pagani M. Hemodynamic and autonomic adjustments to real life stress conditions in humans. Hypertension. 2002;39(1):184-188.
55. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res. 2002;52(1):1-23. Review.
56. von Kanel R, Mills PJ, Fainman C, Dimsdale JE. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosom Med. 2001;63(4):531-544. Review.
57. Vitaliano PP, Scanlan JM, Zhang J, Savage MV, Hirsch IB, Siegler IC. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med. 2002;64(3):418-435.
58. Sharma H, Sen S, Singh A, Bhardwaj NK, Kochupillai V, Singh N. Sudarshan Kriya practitioners exhibit better antioxidant status and lower blood lactate levels. Biol Psychol. 2003;63(3):281-291.
59. Spieker L, Hurlimann D, Ruschitzka F, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation. 2002;105(24):2817-2820.
60. Cannon RO 3rd. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998;44(8 Pt 2):1809-1819. Erratum in: Clin Chem. 1998 Sep;44(9):2070.
61. Sherwood A, Johnson K, Blumenthal JA, Hinderliter AL. Endothelial function and hemodynamic responses during mental stress. Psychosom Med. 1999;61(3):365-370.
62. Kop WJ. The integration of cardiovascular behavioral medicine and psychoneuroimmunology: new developments based on converging research fields. Brain Behav Immun. 2003;17(4):233-237.
63. Tsigos C, Chrousos GP. Hypothalaroic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psyhosom Res. 2002;53(4):865-871.
64. Wold LE, Muralikrishnan D, Albano CB, Norby FL, Ebadi M, Ren J. Insulin-like growth factor I (IGF-1) supplementation prevents diabetes-induced alterations in coenzymes Q9 and Q10. Acta Diabetol. 2003;40(2):85-90.
65. Vickers M, Ikensaio B, Breier B. IGF-1 treatment reduces hyperphagia, obesity, and hypertension in metabolic disorders induced by fetal programming. Endocrinology. 2001;142(9):3964-3973.
66. Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest. 2004;113(1):25-27.
67. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol. 1999;31(11):2049-2061.
68. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Low plasma insulin-like growth factor-1 concentrations predict worsening of insulin-mediated glucose uptake in older people. J Am Geriatr Soc. 1999;47(11):1312-1318.
69. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106(8):939-944.
70. Khan AS, Sane DC, Wannenburg T, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res. 2002;54(1):25-35.
71. Innes KE, Weitzel L, Laudenslager M. Altered metabolic profiles among older mothers with a history of preeclampsia. Gynecol Obstet Invest. 2005;59(4):192-201.
72. Pickering T, Clemow L, Davidson K, Gerin W. Behavioral cardiology - has its time finally arrived? Mt Sinai J Med. 2003;70(2):101-112.
73. Dallman MF, Pecoraro N, Akana SF, et al. Chronic stress and obesity: a new view of "comfort food." Proc Natl Acad Sci U S A. 2003;100(20):11696-11701.
74. Paradies Y. A review of psychosocial stress and chronic disease for 4th world indigenous peoples and African Americans. Ethn Dis. 2006;16(1):295-308.
75. Tafet GE, Bernardini R. Psychoneuroendocrinological links between chronic stress and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):893-903.
76. Goodman E, Whitaker RC. A prospective study of the role of depression in the development and persistence of adolescent obesity. Pediatrics. 2002;110(3):497-504.
77. Nelson TL, Palmer RF, Pedersen NL, Miles TP. Psychological and behavioral predictors of body fat distribution: age and gender effects. Obes Res. 1999;7(2):199-207.
78. Davidson K, Jonas BS, Dixon KE, Markovitz JH. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary Artery Risk Development in Young Adults. Arch Intern Med. 2000;160(19):1495-1500.
79. Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation. 2000;102(15):1773-1779.
80. Weber B, Schweiger U, Deuschle M, Heuser I. Major depression and impaired glucose tolerance. Exp Clin Endocrinol Diabetes. 2000;108(3):187-190.
81. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000;49(10):1255-1260.
82. Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism. 2002;51(12):1573-1577.
83. Chen CC, Lu FH, Wu JS, Chang CJ. Correlation between serum lipid concentrations and psychological distress. Psychiatry Res. 2001;102(2):153-162.
84. Rosmond R, Baghei F, Holm G, Bjorntorp P. Relationships between personality disorders and anthropometry, hormones and metabolism in women. J Endocrinol Invest. 2001;24(3):159-165.
85. Jonas BS, Mussolino ME. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med. 2000;62(4):463-471.
86. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care. 1996;19(10):1097-1102.
87. Everson-Rose SA, Meyer PM, Powell LH, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care. 2004;27(12):2856-2862.
88. Palinkas LA, Lee PP, Barrett-Connor E. A prospective study of Type 2 diabetes and depressive symptoms in the elderly: the Rancho Bernardo Study. Diabet Med. 2004;21(11):1185-1191.
89. Todaro JF, Shen BJ, Niaura R, Spiro A 3rd, Ward KD. Effect of negative emotions on frequency of coronary heart disease (The Normative Aging Study). Am J Cardiol. 2003;92(8):901-906.
90. Severus WE, Littman AB, Stoll AL. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry. 2001;9(6):280-293.
91. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med. 2003;35(1):2-11.
92. Yirmiya R, Pollak Y, Morag M, et al. Illness, cytokines, and depression. Ann N Y Acad Sci. 2000;917:478-487.
93. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003;17 Suppl 1:S119-124.
94. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998;62(7):583-606.
95. Leonard BE, Song C. Stress, depression, and the role of cytokines. Adv Exp Med Biol. 1999;461:251-265.
96. Suarez EC, Lewis JG, Kuhn C. The relation of aggression, hostility, and anger to lipopolysaccharide-stimulated tumor necrosis factor (TNF)-alpha by blood monocytes from normal men. Brain Behav Immun. 2002;16(6):675-684.
97. Hassanain M, Zalcman S, Bhatt S, Siegel A. Interleukin-1 beta in the hypothalamus potentiates feline defensive rage: role of serotonin-2 receptors. Neuroscience. 2003;120(1):227-233.
98. McEwen BS. The neurobiology and neuroendocrinology of stress. Implications for post-traumatic stress disorder from a basic science perspective. Psychiatr Clin North Am. 2002;25(2):469-494, ix.
99. Vanitallie T. Stress: a risk factor for serious illness. Metabolism. 2002;51(6 Suppl 1):40-45.
100. McEwen BS. Protective and damaging effects of stress mediators: the good and bad sides of the response to stress. Metabolism. 2002;51(6 Suppl 1):2-4.
101. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuroendocrine and target tissue-related causes. Int J Obes Rel Metab Disord. 2000;24 Suppl 2:S50-S55.
102. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463(1-3):235-272.
103. Eskandari F, Sternberg EM. Neural-immune interactions in health and disease. Ann N Y Acad Sci. 2002;966:20-27.
104. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Psychoneuroimmunology: psychological influences on immune function and health. J Consult Clin Psychol. 2002;70(3):537-547. Review.
105. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853- 859.
106. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry. 2002;7(3):254-275.
107. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology. 2001;26(8):761-788.
108. McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci. 2001;933:265-277. Review.
109. McEwen B, Magarinos A, Reagan L. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res. 2002;53(4):883-890. Review.
110. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry. 2003;54(3):200-207. Review.
111. Phillips RG, LeDoux JE. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci. 1992;106(2):274-285.
112. Ploghaus A, Narain C, Beckmann CF, et al. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci. 2001;21(24):9896-9903.
113. Lovallo WR. Stress and Health: Biological and Psychological Interactions. Thousand Oaks: Sage Publications, Inc; 1997.
114. Rosmond R. Stress induced disturbances of the HPA axis: a pathway to Type 2 diabetes? Med Sci Monit. 2003;9(2):RA35-RA39.
115. Hauss WH, Bauch HJ, Schulte H. Adrenaline and noradrenaline as possible chemical mediators in the pathogenesis of arteriosclerosis. Ann N Y Acad Sci. 1990;598:91-101.
116. Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J. 1998;135(2 Pt 2):S21-S30. Review.
117. Plante GE. Vascular response to stress in health and disease. Metabolism. 2002;51(6 Suppl 1):25-30.
118. Iacoviello L, D'Adamo MC, De Curtis A, Buczko W, Donati MB. Enhanced vascular plasminogen activator (t-PA) release by epinephrine in aged rats. Thromb Haemost. 1995;73(5):841-844.
119. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest. 2002;25(10):899-904. Review.
120. Mavrogiannis L, Trambakoulos DM, Boomsma F, Osmond DH. The sympathoadrenal system mediates the blood pressure and cardiac effects of human coagulation factor XII-related "new pressor protein." Can J Cardiol. 2002;18(10):1077-1086.
121. Ikarugi H, Taka T, Nakajima S, et al. Norepinephrine, but not epinephrine, enhances platelet reactivity and coagulation after exercise in humans. J App Physiol. 1999;86(1):133-138.
122. Walters JM, Ward GM, Barton J, et al. The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes. Metabolism. 1997;46(12):1448-1453.
123. Keijzers GB, De Galan BE, Tack CJ, Smits P. Caffeine can decrease insulin sensitivity in humans. Diabetes Care. 2002;25(2):364-369.
124. Pickering T. Cardiovascular pathways: socioeconomic status and stress effects on hypertension and cardiovascular function. Ann N Y Acad Sci. 1999;896:262-277. Review.
125. Seematter G, Binnert C, Martin JL, Tappy L. Relationship between stress, inflammation and metabolism. Curr Opin Clin Nutr Metab Care. 2004;7(2):169-173.
126. Black PH. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun. 2003;17(5):350-364.
127. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens. 2001;14(11 Pt 2):304S-309S.
128. Rupp H, Maisch B. Abdominal fat and sympathetic overactivity. From calorie intake to postmenopausal hypertension. Herz. 2003;28(8):668-673.
129. Gutin B, Islam S, Treiber F, Smith C, Manos T. Fasting insulin concentration is related to cardiovascular reactivity to exercise in children. Pediatrics. 1995;96(6):1123-1125.
130. Tripathy D, Aljada A, Dandona P. Free fatty acids (FFA) and endothelial dysfunction; role of increased oxidative stress and inflammation. - to: Steinberg et al. (2002) Vascular function, insulin resistance and fatty acids. Diabetologia. 2003;46(2):300-301.
131. Keaney JF, Jr., Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434-439.
132. West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000;17(3):171-180.
133. Maritim A, Sanders R, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1):24-38. Review.
134. Dhalla N, Temsah R, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18(6):655-673.
135. Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Tract. 2001;54 Suppl 2:S29-S33.
136. Deedwania P. Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diabet Rep. 2003;3(4):289-292.
137. Heine R, Dekker J. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia. 2002;45(4):461-475. Review.
138. Feener EP, King GL. Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail Monit. 2001;1(3):74-82.
139. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3(2):85-101.
140. Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol. 2001;38 Suppl 2:S3-S6. Review.
141. Nazzaro P, Triggiani R, Ciancio L, Scarano AM, Pirrelli AM. Insulin resistance in essential hypertension: a psychophysiological approach to the "chicken and egg" question. Nutr Metab Cardiovasc Dis. 2000;10(5):275-286. Review.
142. McVeigh GE, Cohn JN. Endothelial dysfunction and the metabolic syndrome. Curr Diabet Rep. 2003;3(1):87-92.
143. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003;52(12):2882-2887.
144. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation - the two keystones of ischemia/reperfusion injury. Int J Cardiol. 2002;86(1):41-59.
145. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 1995;25 Suppl 2:S9-S12. Review.
146. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutri Metab Care. 2002;5(4):377-383.
147. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340(2):115-126. Review.
148. Liuzzo G. Atherosclerosis: an inflammatory disease. Rays. 2001;26(4):221-230.
149. Jacobs BL. Adult brain neurogenesis and depression. Brain Behav Immun. 2002;16(5):602-609.
150. Clow A. Cytokines and depression. Int Rev Neurobiol. 2002;52:255-273.
151. Gasparini L, Xu H. Potential roles of insulin and 1GF-1 in Alzheimer's disease. Trends Neurosci. 2003;26(8):404-406.
152. Torres-Aleman I. Serum growth factors and neuroprotective surveillance: focus on IGF-1. Mol Neurobiol. 2000;21(3):153-160. Review.
153. Anderson MF, Aberg MA, Nilsson M, Eriksson PS. Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Devel Brain Res. 2002;134(1-2):115-122.
154. Patel V, Zhang Q, Siddle K, et al. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res. 2001;88(9):895-902.
155. Che W, Lerner-Marmarosh N, Huang Q, et al. Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circ Res. 2002;90(11):1222-1230.
156. Conti E, Andreotti F, Sestito A, et al. Reduced levels of insulin-like growth factor -1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol. 2002;89(8):973-975.
157. Kolaczynski JW, Caro JF. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann Intern Med. 1994;120(1):47-55.
158. Montaron MF, Piazza PV, Aurousseau C, Urani A, Le Moal M, Abrous DN. Implication of corticosteroid receptors in the regulation of hippocampal structural plasticity. Eur J Neurosci. 2003;18(11):3105-3111.
159. Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A. 2001;98(22):12796-12801.
160. Czeh B, Welt T, Fischer AK, et al. Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biol Psychiatry. 2002;52(11):1057-1065.
161. Gould E, Tanapat P, McEwen BS, Flugge G, Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci U S A. 1998;95(6):3168-3171.
162. Garcia R. Stress, metaplasticity, and antidepressants. Curr Mol Med. 2002;2(7):629-638.
163. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301(5634):805-809. Review.
164. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5(3):262-269.
165. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104-9110.
166. Lee AL, Ogle WO, Sapolsky RM. Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord. 2002;4(2):117-128.
167. Garcia R. Stress, synaptic plasticity, and psychopathotogy. Rev Neurosci. 2002;13(3):195-208.